JCS/T2D - We are advocates. We learn. We share. We inform.

Abstract

Explore how well continuous glucose monitor (CGM) readings align with blood glucose meter (BGM) results, using real-world data and a 15-minute pairing window. By tracking percent differences and visualizing trends, it becomes easier to evaluate sensor placement, detect performance issues, and make more confident decisions.

Key Points

• CGM and BGM measure glucose in different body compartments, with CGM readings naturally lagging 5–15 minutes behind blood glucose levels.
• Even properly functioning sensors can show differences—up to 20% variance is considered acceptable under FDA and clinical standards.
• Pairing BGM and CGM readings within a 15-minute window helps identify when differences are expected and when they may indicate sensor issues.
• Sensor placement significantly affects accuracy, with some sites showing more consistent alignment than others.
• Tracking alignment over time supports better decision-making, helping to distinguish between natural fluctuations and device-related discrepancies.

Abstract

An international research team led by Lund University Diabetes Centre has discovered blood-based epigenetic markers that may help predict which people with type 2 diabetes are at risk of serious cardiovascular events. In a study of 752 newly diagnosed participants followed for just over seven years, a scoring tool based on DNA methylation patterns outperformed standard clinical risk calculators, particularly in ruling out low-risk individuals. While further validation is needed, this approach could lead to a simple blood test that supports more personalized prevention and treatment strategies in type 2 diabetes care.

Key Points

• Study Scope: Followed 752 newly diagnosed type 2 diabetes patients for an average of 4 years, identifying 102 major cardiovascular events.
• Main Finding: Developed a DNA methylation-based score using 87 sites that predicted heart risk more accurately than standard clinical risk scores.
• Low-Risk Identification: The tool had a 96% probability of correctly identifying those unlikely to develop cardiovascular disease.
• Limitations: Short follow-up period, limited diversity, moderate positive predictive value, and missing lifestyle data.
• Future Potential: Could evolve into a simple blood test to guide personalized prevention, treatment, and follow-up in type 2 diabetes.

Abstract

Researchers have identified two proteins, RORDEP1 and RORDEP2, produced by certain strains of the gut bacterium Ruminococcus torques, that influence weight, blood sugar, and bone health. Preclinical studies show they increase GLP-1 and PYY, reduce GIP, boost fat burning, and improve liver insulin sensitivity. Early human trials are underway, exploring their potential as next-generation probiotics or protein-based therapies for type 2 diabetes, obesity, and related conditions.

Key Points

• RORDEP1 and RORDEP2 mimic some effects of the exercise hormone irisin and modulate key metabolic hormones.
• Animal studies show reduced weight gain, improved glucose tolerance, and stronger bones with RORDEP treatment.
• Mechanisms include increased satiety hormones, direct fat-burning effects, and improved hepatic insulin sensitivity.
• Potential therapeutic uses range from preventive probiotics to drug combinations enhancing GLP-1 therapy.
• Human trials have started, but clinical availability is likely 10–15 years away.